Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Completed · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia

In brief

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia

Key facts

Study ID

NCT02970292

Run by

ACADIA Pharmaceuticals Inc.

People needed

396

Starts

2016-10-26

Expected to finish

2019-06-25

Last updated by the study team

2020-06-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults patients, between 18 and 55 years of age
• A clinical diagnosis of schizophrenia with a minimum duration of 1 year
• The main background antipsychotic with which the subject is being treated must be one of the antipsychotics listed below:
• Aripiprazole
• Aripiprazole long-acting injectables:
• Abilify Maintena®
• Aristada®
• Risperidone
• Risperidone long-acting injection
• Olanzapine
• Lurasidone
• Cariprazine
• Brexpiprazole
• Asenapine
• Has had a partial but inadequate response to antipsychotic treatment
• Has a history of response to antipsychotic treatment other than clozapine

You may not qualify if…

• Patient has a psychiatric disorder other than schizophrenia
• Patient has a history of resistance to antipsychotic treatment
• A urine drug screen (UDS) result at Baseline that indicates the presence of any tested prohibited substance of potential abuse, except marijuana
• a. Patients with a result indicating the presence of marijuana are permitted if they agree to abstain from marijuana use during the study and the medical monitor approves the subject's participation
• Patient has current evidence of a serious and/or unstable psychiatric, neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
• Patient has had a myocardial infarction in the last six months
• Patient is taking a medication or drug that prolongs the QT interval or has a family or personal history or symptoms of long QT syndrome
• Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

Where it is running

• Study site — Little Rock, Arkansas, United States
• Study site — Rogers, Arkansas, United States
• Study site — Bellflower, California, United States
• Study site — Cerritos, California, United States
• Study site — Culver City, California, United States
• Study site — Lemon Grove, California, United States
• Study site — Long Beach, California, United States
• Study site — San Diego, California, United States
• Study site — San Diego, California, United States
• Study site — Santa Ana, California, United States
• Study site — Torrance, California, United States
• Study site — Boca Raton, Florida, United States
• Study site — Lauderhill, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• Study site — Hoffman Estates, Illinois, United States
• Study site — Lake Charles, Louisiana, United States
• Study site — Catonsville, Maryland, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Berlin, New Jersey, United States
• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.